Payment overview · 2025
General Payments
$425.60
21 reported records · 9 companies
Healthcare provider profile · identity verified
Thomas Wagner, DO
Allopathic & Osteopathic Physicians|Family Medicine · N RIDGEVILLE, OH · NPI 1669464673
Verified facts
What the public records show
CMS Open Payments records show Thomas Wagner, DO received $425.60 in general payments during 2025 across 21 reported records.
Merck Sharp & Dohme LLC accounted for 23.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $101.92 | 23.9% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $77.51 | 18.2% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $68.87 | 16.2% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $58.07 | 13.6% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $35.85 | 8.4% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $30.47 | 7.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.11 | 4.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $16.43 | 3.9% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $16.37 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $425.60 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $101.92 | 5 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $101.92 | 5 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $101.92 | 5 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $80.59 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $60.08 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $58.07 | 3 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $42.43 | 2 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $41.82 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $40.86 | 2 | 2025 |
Source payment records
|
|||||
| PROQUAD Normalized: proquad |
Biological | Merck Sharp & Dohme LLC | $39.00 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $35.85 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $35.85 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $30.47 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $28.01 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $20.11 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.43 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $16.43 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $16.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
63 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
66 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 370 | 101 |
| Amlodipine Besylate | Amlodipine Besylate | 312 | 81 |
| Levothyroxine Sodium | Levothyroxine Sodium | 296 | 89 |
| Omeprazole | Omeprazole | 294 | 80 |
| Gabapentin | Gabapentin | 274 | 48 |
| Lisinopril | Lisinopril | 273 | 70 |
| Metoprolol Succinate | Metoprolol Succinate | 267 | 62 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 258 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 237 | 61 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 236 | 66 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 209 | 28 |
| Alprazolam | Alprazolam | 206 | 40 |
| Metformin Hcl | Metformin Hcl | 184 | 47 |
| Oxycodone Hcl | Oxycodone Hcl | 165 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 152 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 148 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 134 | 40 |
| Celecoxib | Celecoxib | 131 | 37 |
| Furosemide | Furosemide | 121 | 41 |
| Montelukast Sodium | Montelukast Sodium | 120 | 30 |
| Trazodone Hcl | Trazodone Hcl | 111 | 29 |
| Carvedilol | Carvedilol | 110 | 28 |
| Sertraline Hcl | Sertraline Hcl | 108 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 108 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 107 | 19 |
| Prednisone | Prednisone | 107 | 59 |
| Losartan Potassium | Losartan Potassium | 106 | 32 |
| Eliquis | Apixaban | 105 | 22 |
| Simvastatin | Simvastatin | 103 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 102 | 26 |
| Metformin Hcl Er | Metformin Hcl | 100 | 31 |
| Potassium Chloride | Potassium Chloride | 98 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 95 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 91 | 26 |
| Allopurinol | Allopurinol | 87 | 22 |
| Glimepiride | Glimepiride | 85 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 82 | 34 |
| Methylprednisolone | Methylprednisolone | 79 | 57 |
| Azithromycin | Azithromycin | 78 | 50 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 77 | 20 |
| Ezetimibe | Ezetimibe | 72 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 68 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 67 | 16 |
| Jardiance | Empagliflozin | 66 | 18 |
| Bupropion Xl | Bupropion Hcl | 65 | 19 |
| Candesartan Cilexetil | Candesartan Cilexetil | 65 | 15 |
| Alendronate Sodium | Alendronate Sodium | 64 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 64 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 63 | 16 |
| Synthroid | Levothyroxine Sodium | 63 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 62 | 47 |
| Tramadol Hcl | Tramadol Hcl | 62 | 14 |
| Baclofen | Baclofen | 59 | 13 |
| Fentanyl | Fentanyl | 59 | suppressed |
| Atenolol | Atenolol | 55 | 17 |
| Diazepam | Diazepam | 55 | 12 |
| Meloxicam | Meloxicam | 50 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 50 | 14 |
| Amoxicillin | Amoxicillin | 48 | 26 |
| Famotidine | Famotidine | 48 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 47 | 20 |
| Buspirone Hcl | Buspirone Hcl | 46 | suppressed |
| Spironolactone | Spironolactone | 46 | 12 |
| Mirtazapine | Mirtazapine | 45 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 44 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 44 | 13 |
| Ozempic | Semaglutide | 44 | suppressed |
| Pregabalin | Pregabalin | 44 | suppressed |
| Naproxen | Naproxen | 43 | 17 |
| Lorazepam | Lorazepam | 38 | 11 |
| Mounjaro | Tirzepatide | 37 | suppressed |
| Glipizide Er | Glipizide | 36 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | 11 |
| Ibuprofen | Ibuprofen | 36 | 12 |
| Lovastatin | Lovastatin | 36 | suppressed |
| Ondansetron Odt | Ondansetron | 36 | 17 |
| Valacyclovir | Valacyclovir Hcl | 35 | suppressed |
| Fluconazole | Fluconazole | 34 | suppressed |
| Mupirocin | Mupirocin | 34 | 27 |
| Ranolazine Er | Ranolazine | 34 | suppressed |
| Trulicity | Dulaglutide | 34 | suppressed |
| Clonazepam | Clonazepam | 33 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 33 | suppressed |
| Topiramate | Topiramate | 33 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | 11 |
| Glipizide | Glipizide | 31 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 31 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 21 |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 29 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 27 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Oxycontin | Oxycodone Hcl | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 25 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Nystatin | Nystatin | 23 | 11 |
| Dutasteride | Dutasteride | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 19 |
| Finasteride | Finasteride | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 17 |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | 11 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 19 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 15 | suppressed |
| Rivastigmine | Rivastigmine | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Sucralfate | Sucralfate | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Cefdinir | Cefdinir | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Zonisamide | Zonisamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $425.60 · 21 records | Merck Sharp & Dohme LLC | AIRSUPRA, CAPVAXIVE, Dexcom G6 Transmitter, ENFLONSIA, EVENITY, GARDASIL 9, INSPIRE, Korlym, MOUNJARO, PROQUAD, REPATHA, ROTATEQ, UBRELVY, VAXELIS, VAXNEUVANCE, VRAYLAR, Wegovy, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error